Comparison of the automated KRYPTOR chromogranin a assay with the DAKO ELISA

Clinical Laboratory

Volumn 60, Issue 12, 2014, Pages 2103-2106

  Wolf, Magnus ^a   Riedlinger, Isolde ^a   Lehmann, Rainer ^a,b   Häring, Hans Ulrich ^a,b   Schleicher, Erwin ^a,b   Peter, Andreas ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Assay; Chromogranin A; KRYPTOR; Tumor marker

Indexed keywords

CHROMOGRANIN A; CHGA PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CHROMOGRANIN A ASSAY ANALYZER; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY ANALYZER; EVALUATION STUDY; HUMAN; IMMUNOASSAY ANALYZER; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; PREDICTIVE VALUE; REPRODUCIBILITY;

AUTOMATION, LABORATORY; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922033002     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140422     Document Type: Article

References (10)

1. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986;314:1145-51.
2. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-49.
3. Stridsberg M, Eriksson B, Oberg K, et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337-41.
4. Boomsma F, Bhaggoe UM, Man in't Veld AJ, et al. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. ClinChimActa 1995;239:57-63.
5. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001;313:21-9.
6. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001;13:55-8.
7. Passing H, Bablok W. Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II. J Clin Chem Clin Biochem 1984;22:431-45.
8. Bland JM, Altaian DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60.
9. Pirker RA, Pont J, Pohnl R, et al. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998;36:837-40.
10. Korse CM, Baan A, Tesselaar ME. Comparison of the automated chromogranin A assay using KRYPTOR instrumentation with the manual IRMA assay of CisBio. Abstracts of the 9th annual ENETS conference for the diagnosis and treatment of neuroendocrine tumor disease. March 7-9, 2012, Copenhagen, Denmark. Neuroendocrinology 2012;96(suppl 1):1-72.